SCHEMBL9893892

SCHEMBL9893892

CCOC(=O)c1nc(-c2ccccc2)n(-c2cc(Cl)ccc2C)c1-c1cccc(Cl)c1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 0.78
GABRA2 P47869 3/20 0.53
GABRB2 P47870 3/20 0.53
MAPT P10636 3/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
CYP19A1 P11511 1/20 0.45
ELANE P08246 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893673 0.94 MDM2 (0.69) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL9893837 0.94 MDM2 (0.77) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL9893895 0.93 MDM2 (0.67) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL1437102 0.90 MDM2 (0.64) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL9893991 0.90 MDM2 (0.64) MDM2GABRA2GABRB2TRPM8ALDH1A1
SCHEMBL9893974 0.89 MDM2 (0.63) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL9893992 0.89 MDM2 (0.62) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL1443291 0.88 MDM2 (0.63) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL9893742 0.88 MDM2 (0.72) MDM2GABRA2GABRB2MAPTTRPM8
SCHEMBL1443425 0.88 MDM2 (1.00) MDM2GABRA2GABRB2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885GABRA2 4293/4885GABRB2 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.